Logo image of M3V.DE

MEVIS MEDICAL SOLUTIONS AG (M3V.DE) Stock Fundamental Analysis

FRA:M3V - DE000A0LBFE4 - Common Stock

25.6 EUR
-0.6 (-2.29%)
Last: 9/4/2025, 7:00:00 PM
Fundamental Rating

6

Overall M3V gets a fundamental rating of 6 out of 10. We evaluated M3V against 11 industry peers in the Health Care Technology industry. M3V gets an excellent profitability rating and is at the same time showing great financial health properties. M3V has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year M3V was profitable.
M3V had a positive operating cash flow in the past year.
In the past 5 years M3V has always been profitable.
In the past 5 years M3V always reported a positive cash flow from operatings.
M3V.DE Yearly Net Income VS EBIT VS OCF VS FCFM3V.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

1.2 Ratios

The Return On Assets of M3V (17.22%) is better than 100.00% of its industry peers.
With an excellent Return On Equity value of 25.58%, M3V belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
The Return On Invested Capital of M3V (14.00%) is better than 100.00% of its industry peers.
M3V had an Average Return On Invested Capital over the past 3 years of 17.15%. This is significantly above the industry average of 9.32%.
Industry RankSector Rank
ROA 17.22%
ROE 25.58%
ROIC 14%
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
M3V.DE Yearly ROA, ROE, ROICM3V.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

M3V has a better Profit Margin (26.87%) than 100.00% of its industry peers.
M3V's Profit Margin has declined in the last couple of years.
The Operating Margin of M3V (23.58%) is better than 100.00% of its industry peers.
In the last couple of years the Operating Margin of M3V has declined.
The Gross Margin of M3V (97.12%) is better than 81.82% of its industry peers.
M3V's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.58%
PM (TTM) 26.87%
GM 97.12%
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
M3V.DE Yearly Profit, Operating, Gross MarginsM3V.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so M3V is creating value.
M3V has about the same amout of shares outstanding than it did 1 year ago.
M3V has about the same amout of shares outstanding than it did 5 years ago.
There is no outstanding debt for M3V. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
M3V.DE Yearly Shares OutstandingM3V.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
M3V.DE Yearly Total Debt VS Total AssetsM3V.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

M3V has an Altman-Z score of 4.76. This indicates that M3V is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.76, M3V belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
There is no outstanding debt for M3V. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.76
ROIC/WACC1.93
WACC7.27%
M3V.DE Yearly LT Debt VS Equity VS FCFM3V.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.3 Liquidity

M3V has a Current Ratio of 1.52. This is a normal value and indicates that M3V is financially healthy and should not expect problems in meeting its short term obligations.
M3V has a better Current ratio (1.52) than 63.64% of its industry peers.
A Quick Ratio of 1.52 indicates that M3V should not have too much problems paying its short term obligations.
The Quick ratio of M3V (1.52) is better than 72.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.52
M3V.DE Yearly Current Assets VS Current LiabilitesM3V.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

M3V shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.41%.
The earnings per share for M3V have been decreasing by -10.74% on average. This is quite bad
M3V shows a decrease in Revenue. In the last year, the revenue decreased by -2.14%.
The Revenue has been decreasing by -1.25% on average over the past years.
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
M3V.DE Yearly Revenue VS EstimatesM3V.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
M3V.DE Yearly EPS VS EstimatesM3V.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 1 2 3

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

M3V is valuated reasonably with a Price/Earnings ratio of 10.24.
M3V's Price/Earnings ratio is rather cheap when compared to the industry. M3V is cheaper than 81.82% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.07. M3V is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.24
Fwd PE N/A
M3V.DE Price Earnings VS Forward Price EarningsM3V.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, M3V is valued a bit cheaper than 72.73% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, M3V is valued cheaper than 81.82% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.38
EV/EBITDA 9.69
M3V.DE Per share dataM3V.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The excellent profitability rating of M3V may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

M3V has a Yearly Dividend Yield of 3.71%.
Compared to an average industry Dividend Yield of 3.59, M3V pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.46, M3V pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.71%

5.2 History

The dividend of M3V is nicely growing with an annual growth rate of 24.89%!
Dividend Growth(5Y)24.89%
Div Incr Years0
Div Non Decr Years0
M3V.DE Yearly Dividends per shareM3V.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

107.89% of the earnings are spent on dividend by M3V. This is not a sustainable payout ratio.
M3V's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP107.89%
EPS Next 2YN/A
EPS Next 3YN/A
M3V.DE Yearly Income VS Free CF VS DividendM3V.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
M3V.DE Dividend Payout.M3V.DE Dividend Payout, showing the Payout Ratio.M3V.DE Dividend Payout.PayoutRetained Earnings

More info and screens

MEVIS MEDICAL SOLUTIONS AG

FRA:M3V (9/4/2025, 7:00:00 PM)

25.6

-0.6 (-2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-27 2025-05-27
Earnings (Next)01-26 2026-01-26
Inst Owners20.44%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap46.59M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.71%
Yearly Dividend2.7
Dividend Growth(5Y)24.89%
DP107.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 10.24
Fwd PE N/A
P/S 2.75
P/FCF 16.38
P/OCF 14.81
P/B 2.61
P/tB 2.61
EV/EBITDA 9.69
EPS(TTM)2.5
EY9.77%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.56
FCFY6.11%
OCF(TTM)1.73
OCFY6.75%
SpS9.32
BVpS9.79
TBVpS9.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 17.22%
ROE 25.58%
ROCE 19.88%
ROIC 14%
ROICexc 20.72%
ROICexgc 20.72%
OM 23.58%
PM (TTM) 26.87%
GM 97.12%
FCFM 16.76%
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
ROICexc(3y)27.89%
ROICexc(5y)26.51%
ROICexgc(3y)27.89%
ROICexgc(5y)26.51%
ROCE(3y)24.36%
ROCE(5y)24.64%
ROICexcg growth 3Y-4.16%
ROICexcg growth 5Y-6.12%
ROICexc growth 3Y-4.16%
ROICexc growth 5Y-6.1%
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 227.51%
Cap/Sales 1.78%
Interest Coverage 250
Cash Conversion 76.1%
Profit Quality 62.38%
Current Ratio 1.52
Quick Ratio 1.52
Altman-Z 4.76
F-Score4
WACC7.27%
ROIC/WACC1.93
Cap/Depr(3y)151.22%
Cap/Depr(5y)111.1%
Cap/Sales(3y)0.98%
Cap/Sales(5y)0.77%
Profit Quality(3y)80.13%
Profit Quality(5y)97.8%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.41%
EBIT growth 3Y-3.25%
EBIT growth 5Y-10.94%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.74%
FCF growth 3Y-32.08%
FCF growth 5Y-14.82%
OCF growth 1Y-46.25%
OCF growth 3Y-29.89%
OCF growth 5Y-13.63%